Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 15
HOS-086235 · Präparat HOS-083284
Rivaroxaban 10, single dose 600 q12h ↑ 153% ↑ 55%
Inhibition of CYP3A and P-gp lead to increased plasma levels and
pharmacodynamic effects of rivaroxaban which may lead to an increased bleeding
risk. Therefore, the use of ritonavir is not recommended in patients receiving
rivaroxaban.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rivaroxaban (HOS-086236) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 50c78ffce025c1960dde8591775448d03ac689dd3ae246c5ae5d0c29c325175d · Zeichen 22228–22720 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 47
HOS-086431 · Präparat HOS-083284
Rivaroxaban 10, single dose 600 q12h ↑ 153% ↑ 55%
Inhibition of CYP3A and P-gp lead to increased plasma levels and pharmacodynamic
effects of rivaroxaban which may lead to an increased bleeding risk. Therefore, the use of
ritonavir is not recommended in patients receiving rivaroxaban.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rivaroxaban (HOS-086236) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage c00ddfc3ba9f91fc685c1c893747a3509f14a5415f6675f344e616e27f9b873b · Zeichen 23108–23572 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 15
HOS-108884 · Präparat HOS-093083
For patients who have completed
the ramp-up phase and are on a
steady daily dose of venetoclax,
reduce the venetoclax dose by at
least 75% when used with strong
CYP3A inhibitors (refer to the
venetoclax SmPC for dosing
instructions). Patients should be
closely monitored for signs related
to venetoclax toxicities.
Anticoagulants
Warfarin Warfarin: It is recommended that INR
Concentrations may be affected (international normalised ratio) be
when co-administered with monitored.
lopinavir/ritonavir due to
CYP2C9 induction.
Rivaroxaban Rivaroxaban: Co-administration of rivaroxaban
AUC: ↑ 153% and Kaletra may increase
(Ritonavir 600 mg twice Cmax: ↑ 55% rivaroxaban exposure which may
daily) Due to CYP3A and P-gp increase the risk of bleeding.
inhibition by lopinavir/ritonavir. The use of rivaroxaban is not
recommended in patients receiving
concomitant treatment with
Kaletra (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): venetoclax (HOS-086143) rivaroxaban (HOS-086236) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 5c75313975c3d550f186691732eade756ee17474da9f35bb7423f4bee955c1ce · Zeichen 21495–23493 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52
HOS-109010 · Präparat HOS-093083
For patients who have completed the
ramp-up phase and are on a steady
daily dose of venetoclax, reduce the
venetoclax dose by at least 75%
when used with strong CYP3A
inhibitors (refer to the venetoclax
SmPC for dosing instructions).
Patients should be closely monitored
for signs related to venetoclax
toxicities.
Anticoagulants
Warfarin Warfarin: It is recommended that INR
Concentrations may be affected (international normalised ratio) be
when co-administered with monitored.
lopinavir/ritonavir due to
CYP2C9 induction.
Rivaroxaban Rivaroxaban: Co-administration of rivaroxaban and
AUC: ↑ 153% Kaletra may increase rivaroxaban
(Ritonavir 600 mg twice Cmax: ↑ 55% exposure which may increase the risk
daily) Due to CYP3A and P-gp of bleeding.
inhibition by lopinavir/ritonavir. The use of rivaroxaban is not
recommended in patients receiving
concomitant treatment with Kaletra
(see section 4.4).
Dabigatran etexilate, Dabigatran etexilate, Clinical monitoring and/or dose
Edoxaban Edoxaban: reduction of the direct oral
Serum concentrations may be anticoagulants (DOAC) should be
increased due to Pgp inhibition by considered when a DOAC
lopinavir/ritonavir. transported by P-gp but not
metabolised by CYP3A4, including
dabigatran etexilate and edoxaban, is
co-administered with Kaletra.
Anticonvulsants
Phenytoin Phenytoin: Caution should be exercised in
Steady-state concentrations was administering phenytoin with Kaletra.
moderately decreased due to Phenytoin levels should be monitored
CYP2C9 and CYP2C19 induction when co-administering with Kaletra.
by lopinavir/ritonavir. When co-administered with
phenytoin, an increase of Kaletra
Lopinavir: dosage may be envisaged. Dose
Concentrations are decreased due adjustment has not been evaluated in
to CYP3A induction by clinical practice.
phenytoin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): venetoclax (HOS-086143) rivaroxaban (HOS-086236) edoxaban (HOS-086234) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 092834c32db98766e5109cb3ff4d0c6a8ea77721ca8064bfcdfc67660162c006 · Zeichen 20961–24616 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 87–88
HOS-109085 · Präparat HOS-093083
87
Rivaroxaban Rivaroxaban: Co-administration of rivaroxaban
AUC: ↑ 153% and Kaletra may increase
(Ritonavir 600 mg twice Cmax: ↑ 55% rivaroxaban exposure which may
daily) Due to CYP3A and P-gp increase the risk of bleeding.
inhibition by lopinavir/ritonavir. The use of rivaroxaban is not
recommended in patients receiving
concomitant treatment with Kaletra
(see section 4.4).
Dabigatran etexilate, Dabigatran etexilate, Clinical monitoring and/or dose
Edoxaban Edoxaban: reduction of the direct oral
Serum concentrations may be anticoagulants (DOAC) should be
increased due to Pgp inhibition by considered when a DOAC
lopinavir/ritonavir. transported by P-gp but not
metabolised by CYP3A4, including
dabigatran etexilate and edoxaban,
is co-administered with Kaletra.
Anticonvulsants
Phenytoin Phenytoin: Caution should be exercised in
Steady-state concentrations was administering phenytoin with
moderately decreased due to Kaletra.
CYP2C9 and CYP2C19 induction Phenytoin levels should be
by lopinavir/ritonavir. monitored when co-administering
with Kaletra.
Lopinavir: When co-administered with
Concentrations are decreased due phenytoin, an increase of Kaletra
to CYP3A induction by dosage may be envisaged. Dose
phenytoin. adjustment has not been evaluated
in clinical practice.
Kaletra must not be administered
once daily in combination with
phenytoin.
Carbamazepine and Carbamazepine: Caution should be exercised in
Phenobarbital Serum concentrations may be administering carbamazepine or
increased due to CYP3A phenobarbital with Kaletra.
inhibition by lopinavir/ritonavir. Carbamazepine and phenobarbital
levels should be monitored when
Lopinavir: co-administering with Kaletra.
Concentrations may be decreased When co-administered with
due to CYP3A induction by carbamazepine or phenobarbital, an
carbamazepine and phenobarbital. increase of Kaletra dosage may be
envisaged. Dose adjustment has not
been evaluated in clinical practice.
Kaletra must not be administered
once daily in combination with
carbamazepine and phenobarbital.
Lamotrigine and Lamotrigine: Patients should be monitored
Valproate AUC: ↓ 50% closely for a decreased VPA effect
Cmax: ↓ 46% when Kaletra and valproic acid or
Cmin: ↓ 56% valproate are given concomitantly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproate (HOS-085955) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) rivaroxaban (HOS-086236) edoxaban (HOS-086234) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 0668c273c88d1ae41827a69ac1504dff6543bd6b0d2a053e402140143e6219fb · Zeichen 22156–26627 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 17
HOS-112090 · Präparat HOS-093615
The decrease in AUC, Cmax, and Cmin was
not mitigated when an increased dose of
REYATAZ/ritonavir (400/100 mg once
daily) was temporally separated from
omeprazole by 12 hours. Although not
studied, similar results are expected with
other proton pump inhibitors. This
decrease in atazanavir exposure might
negatively impact the efficacy of
atazanavir. The mechanism of interaction
is decreased solubility of atazanavir as
intra-gastric pH increases with proton
pump inhibitors.
Antacids
Antacids and medicinal Reduced plasma concentrations of REYATAZ should be administered
products containing buffers atazanavir may be the consequence of 2 hours before or 1 hour after
increased gastric pH if antacids, including antacids or buffered medicinal
buffered medicinal products, are products.
administered with REYATAZ.
ALPHA 1-ADRENORECEPTOR ANTAGONIST
Alfuzosin Potential for increased alfuzosin Co-administration of alfuzosin with
concentrations which can result in REYATAZ is contraindicated
hypotension. The mechanism of (see section 4.3)
interaction is CYP3A4 inhibition by
REYATAZ and/or ritonavir.
ANTICOAGULANTS
Direct-acting oral anticoagulants (DOACs)
Apixaban Potential for increased apixaban and Co-administration of apixaban or
Rivaroxaban rivaroxaban concentrations which can rivaroxaban and REYATAZ with
result in a higher risk of bleeding. ritonavir is not recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) rivaroxaban (HOS-086236) apixaban (HOS-112091) ritonavir (HOS-084521) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage c2e1c404625f053010d018b68c609db0fa46e4ca86fdb8aa482fd8bcd7905174 · Zeichen 37490–39803 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 24–25
HOS-112119 · Präparat HOS-093615
24
In case of withdrawal of ritonavir from the recommended atazanavir-boosted regimen
(see section 4.4)
The same recommendations for drug interactions would apply except:
that co-administration is not recommended with tenofovir, proton pump inhibitors, and
buprenorphine and contraindicated with carbamazepine, phenytoin and phenobarbital.
that co-administration with famotidine is not recommended but if required, atazanavir without
ritonavir should be administered either 2 hours after famotidine or 12 hours before. No single
dose of famotidine should exceed 20 mg, and the total daily dose of famotidine should not
exceed 40 mg.
the need to consider that:
co-administration of apixaban, dabigatran, or rivaroxaban and REYATAZ without
ritonavir may affect apixaban, dabigatran, or rivaroxaban concentrations
co-administration of voriconazole and REYATAZ without ritonavir may affect atazanavir
concentrations
co-administration of fluticasone and REYATAZ without ritonavir may increase
fluticasone concentrations relative to fluticasone given alone
if an oral contraceptive is administered with REYATAZ without ritonavir, it is
recommended that the oral contraceptive contain no more than 30 μg of ethinyloestradiol
no dose adjustment of lamotrigine is required
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lamotrigine (HOS-086242) fluticasone (HOS-108914) phenobarbital (HOS-085617) carbamazepine (HOS-085618) famotidine (HOS-112087) dabigatran (HOS-112096) buprenorphine (HOS-086193) rivaroxaban (HOS-086236) voriconazole (HOS-084524) apixaban (HOS-112091) ritonavir (HOS-084521) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage e782985711b73a21e78ab499d92e8fece89fe8ca127ddbacf1a99dce682dcc07 · Zeichen 75495–76934 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 52–53
HOS-112184 · Präparat HOS-093615
52
Medicinal products by Interaction Recommendations
therapeutic area concerning co-administration
ANTICOAGULANTS
Direct-acting oral anticoagulants (DOACs)
Apixaban Potential for increased apixaban and Co-administration of apixaban
Rivaroxaban rivaroxaban concentrations which can or rivaroxaban and REYATAZ
result in a higher risk of bleeding. with ritonavir is not
recommended.
The mechanism of interaction is inhibition
of CYP3A4/and P-gp by
REYATAZ/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rivaroxaban (HOS-086236) apixaban (HOS-112091) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 0e1e37e383b22e279dabd523bbd3ffce33698efda1183ff54541e6b52e2f0ce6 · Zeichen 40304–41158 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 15–16
HOS-116363 · Präparat HOS-094447
15
ANTIBIOTIC
Clarithromycin clarithromycin AUC ↑ 57% Caution should be exercised when
500 mg twice daily
clarithromycin Cmin ↑ 174% clarithromycin is combined with
clarithromycin Cmax ↑ 26% boosted PREZISTA.
#
darunavir AUC ↓ 13%
#
darunavir Cmin ↑ 1% For patients with renal impairment
# the Summary of Product
darunavir Cmax ↓ 17%
Characteristics for clarithromycin
14-OH-clarithromycin concentrations
should be consulted for the
were not detectable when combined with
recommended dose.
PREZISTA/ritonavir.
(↑ clarithromycin from CYP3A inhibition
and possible P-gp inhibition)
ANTICOAGULANT/PLATELET AGGREGATION INHIBITOR
Apixaban Not studied. Co-administration of The use of boosted PREZISTA
Rivaroxaban boosted PREZISTA with these with a direct oral anticoagulant
anticoagulants may increase (DOAC) that is metabolised by
concentrations of the anticoagulant. CYP3A4 and transported by P-gp
(CYP3A and/or P-gp inhibition) is not recommended as this may
lead to an increased bleeding risk.
Dabigatran etexilate dabigatran etexilate (150 mg): Darunavir/ritonavir:
Edoxaban darunavir/ritonavir 800/100 mg single Clinical monitoring and/or dose
dose: reduction of the DOAC should be
dabigatran AUC ↑ 72% considered when a DOAC
dabigatran Cmax ↑ 64% transported by P-gp but not
metabolised by CYP3A4,
darunavir/ritonavir 800/100 mg once including dabigatran etexilate and
daily: edoxaban, is co-administered with
dabigatran AUC ↑ 18% PREZISTA/rtv.
dabigatran Cmax ↑ 22%
Darunavir/cobicistat:
darunavir/cobicistat 800/150 mg single Clinical monitoring and dose
dose: reduction is required when a
dabigatran AUC ↑ 164% DOAC transported by P-gp but not
dabigatran Cmax ↑ 164% metabolised by CYP3A4,
including dabigatran etexilate and
darunavir/cobicistat 800/150 mg once edoxaban, is co-administered with
daily: PREZISTA/cobi.
dabigatran AUC ↑ 88%
dabigatran Cmax ↑ 99%
Ticagrelor Concomitant administration of
Based on theoretical considerations,
boosted PREZISTA with ticagrelor
co-administration of boosted PREZISTA
is contraindicated (see section 4.3).
with ticagrelor may increase
concentrations of ticagrelor (CYP3A
and/or P-glycoprotein inhibition).
Clopidogrel Co-administration of clopidogrel
Not studied. Co-administration of
with boosted PREZISTA is not
clopidogrel with boosted PREZISTA is
recommended. Use of other
expected to decrease clopidogrel active
antiplatelets not affected by CYP
metabolite plasma concentration, which
inhibition or induction (e.g.
may reduce the antiplatelet activity of
prasugrel) is recommended.
clopidogrel.
Warfarin Not studied. Warfarin concentrations may It is recommended that the
be affected when co-administered with international normalised ratio
boosted PREZISTA. (INR) be monitored when warfarin
is combined with boosted
PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) cobicistat (HOS-088111) dabigatran (HOS-112096) rivaroxaban (HOS-086236) lead (HOS-085592) clopidogrel (HOS-087927) clarithromycin (HOS-084517) edoxaban (HOS-086234) apixaban (HOS-112091) prasugrel (HOS-112066) ritonavir (HOS-084521) dabigatran etexilate (HOS-086233) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage c517feec8afcc30d3aa41f1410083f5273e19d3aef8a7a29cc68426909e25762 · Zeichen 29322–34850 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 57
HOS-116517 · Präparat HOS-094447
Amiodarone PREZISTA co-administered with
Bepridil low dose ritonavir and
Dronedarone amiodarone, bepridil, dronedarone,
Ivabradine ivabradine, quinidine, or
Quinidine ranolazine is contraindicated (see
Ranolazine section 4.3).
Digoxin digoxin AUC ↑ 61% Given that digoxin has a narrow
0.4 mg single dose digoxin Cmin ND therapeutic index, it is
digoxin Cmax ↑ 29% recommended that the lowest
(↑ digoxin from probable inhibition of possible dose of digoxin should
P-gp) initially be prescribed in case
digoxin is given to patients on
darunavir/ritonavir therapy. The
digoxin dose should be carefully
titrated to obtain the desired
clinical effect while assessing the
overall clinical state of the subject.
ANTIBIOTIC
Clarithromycin clarithromycin AUC ↑ 57% Caution should be exercised when
500 mg twice daily
clarithromycin Cmin ↑ 174% clarithromycin is combined with
clarithromycin Cmax ↑ 26% PREZISTA co-administered with
#
darunavir AUC ↓ 13% low dose ritonavir.
#
darunavir Cmin ↑ 1%
# For patients with renal impairment
darunavir Cmax ↓ 17%
the Summary of Product
14-OH-clarithromycin concentrations
Characteristics for clarithromycin
were not detectable when combined with
should be consulted for the
PREZISTA/ritonavir.
recommended dose.
(↑ clarithromycin from CYP3A inhibition
and possible P-gp inhibition)
ANTICOAGULANT/PLATELET AGGREGATION INHIBITOR
Apixaban Not studied. Co-administration of The use of boosted PREZISTA
Rivaroxaban boosted PREZISTA with these with a direct oral anticoagulant
anticoagulants may increase (DOAC) that is metabolised by
concentrations of the anticoagulant. CYP3A4 and transported by P-gp
(CYP3A and/or P-gp inhibition) is not recommended as this may
lead to an increased bleeding risk.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) rivaroxaban (HOS-086236) lead (HOS-085592) clarithromycin (HOS-084517) apixaban (HOS-112091) ivabradine (HOS-109426) ritonavir (HOS-084521) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 227bb2dae3a2a6739ad7d75460b7010eb52122480b556e1f4afdf1e753dc6670 · Zeichen 21078–24599 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 97
HOS-116608 · Präparat HOS-094447
Amiodarone Co-administration of boosted
Bepridil PREZISTA and amiodarone,
Dronedarone bepridil, dronedarone, ivabradine,
Ivabradine quinidine, or ranolazine is
Quinidine contraindicated (see section 4.3).
Ranolazine
Digoxin digoxin AUC ↑ 61% Given that digoxin has a narrow
0.4 mg single dose digoxin Cmin ND therapeutic index, it is
digoxin Cmax ↑ 29% recommended that the lowest
(↑ digoxin from probable inhibition of possible dose of digoxin should
P-gp) initially be prescribed in case
digoxin is given to patients on
boosted PREZISTA therapy. The
digoxin dose should be carefully
titrated to obtain the desired
clinical effect while assessing the
overall clinical state of the subject.
ANTIBIOTIC
Clarithromycin clarithromycin AUC ↑ 57% Caution should be exercised when
500 mg twice daily
clarithromycin Cmin ↑ 174% clarithromycin is combined with
clarithromycin Cmax ↑ 26% boosted PREZISTA.
#
darunavir AUC ↓ 13%
#
darunavir Cmin ↑ 1% For patients with renal impairment
# the Summary of Product
darunavir Cmax ↓ 17%
Characteristics for clarithromycin
14-OH-clarithromycin concentrations
should be consulted for the
were not detectable when combined with
recommended dose.
PREZISTA/ritonavir.
(↑ clarithromycin from CYP3A inhibition
and possible P-gp inhibition)
ANTICOAGULANT/PLATELET AGGREGATION INHIBITOR
Apixaban Not studied. Co-administration of The use of boosted PREZISTA
Rivaroxaban boosted PREZISTA with these with a direct oral anticoagulant
anticoagulants may increase (DOAC) that is metabolised by
concentrations of the anticoagulant. CYP3A4 and transported by P-gp
(CYP3A and/or P-gp inhibition) is not recommended as this may
lead to an increased bleeding risk.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) rivaroxaban (HOS-086236) lead (HOS-085592) clarithromycin (HOS-084517) apixaban (HOS-112091) ivabradine (HOS-109426) ritonavir (HOS-084521) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage d32b19556a6cce04cd413a7b7e735b8fbe64621522b345e338c67799d622d39b · Zeichen 27793–31178 im Abschnitt
Gegenanzeigen · Pradaxa
Pradaxa 75 mg hard capsules · Abschnitt 4.3 · PDF-Seite 6
HOS-118621 · Präparat HOS-094855
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
• Severe renal impairment (CrCL < 30 mL/min) in adult patients
• eGFR < 50 mL/min/1.73 m2 in paediatric patients
• Active clinically significant bleeding
• Lesion or condition, if considered a significant risk factor for major bleeding. This may include
current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of
bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent
intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous
malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities
• Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low
molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux etc),
oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under specific circumstances.
These are switching anticoagulant therapy (see section 4.2), when UFH is given at doses
necessary to maintain an open central venous or arterial catheter or when UFH is given during
catheter ablation for atrial fibrillation (see section 4.5)
• Hepatic impairment or liver disease expected to have any impact on survival
• Concomitant treatment with the following strong P-gp inhibitors: systemic ketoconazole,
cyclosporine, itraconazole, dronedarone and the fixed-dose combination
glecaprevir/pibrentasvir (see section 4.5)
• Prosthetic heart valves requiring anticoagulant treatment (see section 5.1).
6
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) fondaparinux (HOS-110096) glecaprevir (HOS-086297) heparin (HOS-086930) rivaroxaban (HOS-086236) itraconazole (HOS-084516) apixaban (HOS-112091) cyclosporine (HOS-084512) enoxaparin (HOS-118623) dalteparin (HOS-118624) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage 58c4826e564b5c5b7f1abc93ec498be4215981e3fc8a5222c2a54f71816b01c4 · Zeichen 0–1751 im Abschnitt
Gegenanzeigen · Pradaxa
Pradaxa 110 mg hard capsules · Abschnitt 4.3 · PDF-Seite 38–39
HOS-118701 · Präparat HOS-094855
38
bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent
intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous
malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities
• Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low
molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux etc),
oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under specific circumstances.
These are switching anticoagulant therapy (see section 4.2), when UFH is given at doses
necessary to maintain an open central venous or arterial catheter or when UFH is given during
catheter ablation for atrial fibrillation (see section 4.5)
• Hepatic impairment or liver disease expected to have any impact on survival
• Concomitant treatment with the following strong P-gp inhibitors: systemic ketoconazole,
cyclosporine, itraconazole, dronedarone and the fixed-dose combination
glecaprevir/pibrentasvir (see section 4.5)
• Prosthetic heart valves requiring anticoagulant treatment (see section 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) fondaparinux (HOS-110096) glecaprevir (HOS-086297) heparin (HOS-086930) rivaroxaban (HOS-086236) itraconazole (HOS-084516) apixaban (HOS-112091) cyclosporine (HOS-084512) enoxaparin (HOS-118623) dalteparin (HOS-118624) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage ec2e999673d5b90adcb3018232692e9cba05e46844ff8f9fe74dad3d32d8172e · Zeichen 520–1753 im Abschnitt
Gegenanzeigen · Pradaxa
Pradaxa 150 mg hard capsules · Abschnitt 4.3 · PDF-Seite 78–79
HOS-118789 · Präparat HOS-094855
78
bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent
intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous
malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities
• Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low
molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux etc),
oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under specific circumstances.
These are switching anticoagulant therapy (see section 4.2), when UFH is given at doses
necessary to maintain an open central venous or arterial catheter or when UFH is given during
catheter ablation for atrial fibrillation (see section 4.5)
• Hepatic impairment or liver disease expected to have any impact on survival
• Concomitant treatment with the following strong P-gp inhibitors: systemic ketoconazole,
cyclosporine, itraconazole, dronedarone and the fixed-dose combination
glecaprevir/pibrentasvir (see section 4.5)
• Prosthetic heart valves requiring anticoagulant treatment (see section 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) fondaparinux (HOS-110096) glecaprevir (HOS-086297) heparin (HOS-086930) rivaroxaban (HOS-086236) itraconazole (HOS-084516) apixaban (HOS-112091) cyclosporine (HOS-084512) enoxaparin (HOS-118623) dalteparin (HOS-118624) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage 30c550ec0ab8ef152af1fe03e09c53747fb57851a2196eef5c1b464bb4db5f2f · Zeichen 520–1753 im Abschnitt
Gegenanzeigen · Pradaxa
Pradaxa 20 mg coated granules Pradaxa 30 mg coated granules Pradaxa 40 mg coated granules Pradaxa 50 mg coated granules Pradaxa 110 mg coated granules Pradaxa 150 mg coated granules · Abschnitt 4.3 · PDF-Seite 113–114
HOS-118875 · Präparat HOS-094855
113
intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous
malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities
• Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low
molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux etc),
oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under specific circumstances.
These are switching anticoagulant therapy (see section 4.2) or when UFH is given at doses
necessary to maintain an open central venous or arterial catheter (see section 4.5).
• Hepatic impairment or liver disease expected to have any impact on survival
• Concomitant treatment with the following strong P-gp inhibitors: systemic ketoconazole,
cyclosporine, itraconazole, dronedarone and the fixed-dose combination
glecaprevir/pibrentasvir (see section 4.5)
• Prosthetic heart valves requiring anticoagulant treatment (see section 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) fondaparinux (HOS-110096) glecaprevir (HOS-086297) heparin (HOS-086930) rivaroxaban (HOS-086236) itraconazole (HOS-084516) apixaban (HOS-112091) cyclosporine (HOS-084512) enoxaparin (HOS-118623) dalteparin (HOS-118624) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage 308c96bdc025271910c30c2a89b1c7a62217151b0bbcfcdea4bed4d500b70ffb · Zeichen 551–1650 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 75 mg hard capsules · Abschnitt 4.5 · PDF-Seite 13
HOS-118650 · Präparat HOS-094855
There is no or only limited experience with the following treatments which may increase the risk of
bleeding when used concomitantly with dabigatran etexilate: anticoagulants such as unfractionated
heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux,
desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral
anticoagulants (see section 4.3), and antiplatelet aggregation medicinal products such as GPIIb/IIIa
receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sulfinpyrazone (HOS-089177) fondaparinux (HOS-110096) dextran (HOS-118654) vitamin K (HOS-091176) heparin (HOS-086930) rivaroxaban (HOS-086236) prasugrel (HOS-112066) desirudin (HOS-118651) ticlopidine (HOS-087946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage a2f6a9478f57630a4c855e173bebe15e2bee9f3bdbecaa93d3fe6350a29c6ded · Zeichen 8130–8723 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 110 mg hard capsules · Abschnitt 4.5 · PDF-Seite 46
HOS-118725 · Präparat HOS-094855
There is no or only limited experience with the following treatments which may increase the risk of
bleeding when used concomitantly with dabigatran etexilate: anticoagulants such as unfractionated
heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux,
desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral
anticoagulants (see section 4.3), and antiplatelet aggregation medicinal products such as GPIIb/IIIa
receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sulfinpyrazone (HOS-089177) fondaparinux (HOS-110096) dextran (HOS-118654) vitamin K (HOS-091176) heparin (HOS-086930) rivaroxaban (HOS-086236) prasugrel (HOS-112066) desirudin (HOS-118651) ticlopidine (HOS-087946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage a2f6a9478f57630a4c855e173bebe15e2bee9f3bdbecaa93d3fe6350a29c6ded · Zeichen 8103–8696 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 150 mg hard capsules · Abschnitt 4.5 · PDF-Seite 86
HOS-118814 · Präparat HOS-094855
There is no or only limited experience with the following treatments which may increase the risk of
bleeding when used concomitantly with dabigatran etexilate: anticoagulants such as unfractionated
heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux,
desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral
anticoagulants (see section 4.3), and antiplatelet aggregation medicinal products such as GPIIb/IIIa
receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sulfinpyrazone (HOS-089177) fondaparinux (HOS-110096) dextran (HOS-118654) vitamin K (HOS-091176) heparin (HOS-086930) rivaroxaban (HOS-086236) prasugrel (HOS-112066) desirudin (HOS-118651) ticlopidine (HOS-087946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage a2f6a9478f57630a4c855e173bebe15e2bee9f3bdbecaa93d3fe6350a29c6ded · Zeichen 8119–8712 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 20 mg coated granules Pradaxa 30 mg coated granules Pradaxa 40 mg coated granules Pradaxa 50 mg coated granules Pradaxa 110 mg coated granules Pradaxa 150 mg coated granules · Abschnitt 4.5 · PDF-Seite 120
HOS-118901 · Präparat HOS-094855
There is no or only limited experience with the following treatments which may increase the risk of
bleeding when used concomitantly with dabigatran etexilate: anticoagulants such as unfractionated
heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux,
desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral
anticoagulants (see section 4.3), and antiplatelet aggregation medicinal products such as GPIIb/IIIa
receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sulfinpyrazone (HOS-089177) fondaparinux (HOS-110096) dextran (HOS-118654) vitamin K (HOS-091176) heparin (HOS-086930) rivaroxaban (HOS-086236) prasugrel (HOS-112066) desirudin (HOS-118651) ticlopidine (HOS-087946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage a2f6a9478f57630a4c855e173bebe15e2bee9f3bdbecaa93d3fe6350a29c6ded · Zeichen 8244–8837 im Abschnitt
Wechselwirkungen · Bridion
Bridion 100 mg/mL solution for injection · Abschnitt 4.5 · PDF-Seite 7
HOS-119618 · Präparat HOS-094981
In a study in volunteers doses of 4 mg/kg and 16 mg/kg of sugammadex resulted in maximum mean
prolongations of aPTT by 17 and 22% respectively and of PT(INR) by 11 and 22% respectively.
These limited mean aPTT and PT(INR) prolongations were of short duration (≤ 30 minutes).
In in vitro experiments a pharmacodynamic interaction (aPTT and PT prolongation) was noted with
vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban and
dabigatran (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vitamin K (HOS-091176) heparin (HOS-086930) dabigatran (HOS-112096) rivaroxaban (HOS-086236) heparinoids (HOS-119619)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-06T17:24:00Z · SHA-256 c678da8df4e0f062258fc41e9097613813dcaaecc8e8156e47a2d8252e6efd4e · Passage 135d9c06902241627f554d65e6f46425730be845dd850dccf7985e25d3c78098 · Zeichen 4832–5329 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.